SEC filing · 8-K

Alector, Inc.: Quarterly results

Alector entered into an exclusive global licensing agreement with Genentech for its AL050 program and will receive a $100 million upfront payment.

Filed October 5, 2026

Positive for the company

What happened

Alector granted Genentech exclusive global rights to develop and commercialize its AL050 program for Parkinson's disease and other neurodegenerative diseases.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.01) All documents of this filing

Back to Alector, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.